Pfizer Inc Total Liabilities
Pfizer Inc total liabilities. Based on the latest financial reports, Pfizer Inc (PFE) has total liabilities worth $115.64 Billion USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check PFE cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Pfizer Inc (1985–2025)
Total liabilities of Pfizer Inc from 1985 to 2025. This chart illustrates how Pfizer Inc's total liabilities have evolved over time, based on quarterly financial data. Explore Pfizer Inc (PFE) long-term investment share to see how much of total assets are deployed in long-term investments.
Pfizer Inc Competitors by Total Liabilities
The table below lists competitors of Pfizer Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
The TJX Companies Inc
NYSE:TJX
|
USA | $25.75 Billion |
|
Walt Disney Company DRC
BA:DISN
|
Argentina | AR$87.90 Billion |
|
Contemporary Amperex Technology Co Ltd Class A
SHE:300750
|
China | CN¥724.93 Billion |
|
Sumitomo Mitsui Financial Group Inc
NYSE:SMFG
|
USA | $313.93 Trillion |
|
Marvell Technology Group Ltd
NASDAQ:MRVL
|
USA | $9.02 Billion |
|
Southern Copper Corporation
NYSE:SCCO
|
USA | $11.42 Billion |
|
Banco Santander S.A
F:BSDK
|
Germany | €1.74 Trillion |
|
Deutsche Telekom AG
XETRA:DTE
|
Germany | €195.56 Billion |
Liability Composition Analysis (1985–2025)
This chart breaks down Pfizer Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see PFE total asset value.
Liquidity & Leverage Metrics
Pfizer Inc Total Liabilities Ratios Explained
Pfizer Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.27 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.36 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.57 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Pfizer Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Pfizer Inc (1985–2025)
The table below shows the annual total liabilities of Pfizer Inc from 1985 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $121.39 Billion | -2.81% |
| 2024-12-31 | $124.90 Billion | -8.97% |
| 2023-12-31 | $137.21 Billion | +35.47% |
| 2022-12-31 | $101.29 Billion | -2.62% |
| 2021-12-31 | $104.01 Billion | +14.61% |
| 2020-12-31 | $90.76 Billion | -12.77% |
| 2019-12-31 | $104.04 Billion | +8.76% |
| 2018-12-31 | $95.66 Billion | -4.47% |
| 2017-12-31 | $100.14 Billion | -10.41% |
| 2016-12-31 | $111.78 Billion | +9.09% |
| 2015-12-31 | $102.46 Billion | +4.93% |
| 2014-12-31 | $97.65 Billion | +2.27% |
| 2013-12-31 | $95.48 Billion | -8.30% |
| 2012-12-31 | $104.12 Billion | -1.20% |
| 2011-12-31 | $105.38 Billion | -1.28% |
| 2010-12-31 | $106.75 Billion | -12.86% |
| 2009-12-31 | $122.50 Billion | +129.37% |
| 2008-12-31 | $53.41 Billion | +6.51% |
| 2007-12-31 | $50.14 Billion | +13.67% |
| 2006-12-31 | $44.11 Billion | -13.85% |
| 2005-12-31 | $51.21 Billion | -6.56% |
| 2004-12-31 | $54.80 Billion | +6.62% |
| 2003-12-31 | $51.40 Billion | +94.65% |
| 2002-12-31 | $26.41 Billion | +26.59% |
| 2001-12-31 | $20.86 Billion | +19.65% |
| 2000-12-31 | $17.43 Billion | +0.07% |
| 1999-12-31 | $17.42 Billion | +83.54% |
| 1998-12-31 | $9.49 Billion | +34.49% |
| 1997-12-31 | $7.06 Billion | -7.90% |
| 1996-12-31 | $7.66 Billion | +6.79% |
| 1995-12-31 | $7.18 Billion | +6.54% |
| 1994-12-31 | $6.74 Billion | +24.14% |
| 1993-12-31 | $5.43 Billion | +12.19% |
| 1992-12-31 | $4.84 Billion | +5.74% |
| 1991-12-31 | $4.57 Billion | +16.35% |
| 1990-12-31 | $3.93 Billion | +4.42% |
| 1989-12-31 | $3.76 Billion | +12.84% |
| 1988-12-31 | $3.34 Billion | +9.75% |
| 1987-12-31 | $3.04 Billion | +73.88% |
| 1986-12-31 | $1.75 Billion | +13.86% |
| 1985-12-31 | $1.54 Billion | -- |
About Pfizer Inc
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret b… Read more